Clinical characteristics of bloodstream infections due to ampicillin-sulbactam-resistant, non-extended-spectrum-β-lactamase-producing Escherichia coli and the role of TEM-1 hyperproduction by Waltner-Toews, RI et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2011, p. 495–501 Vol. 55, No. 2
0066-4804/11/$12.00 doi:10.1128/AAC.00797-10
Copyright © 2011, American Society for Microbiology. All Rights Reserved.
Clinical Characteristics of Bloodstream Infections Due to
Ampicillin-Sulbactam-Resistant, Non-Extended-
Spectrum--Lactamase-Producing Escherichia coli
and the Role of TEM-1 Hyperproduction
Rebecca I. Waltner-Toews,1† David L. Paterson,1,2 Zubair A. Qureshi,1 Hanna E. Sidjabat,1,2
Jennifer M. Adams-Haduch,1 Kathleen A. Shutt,1 Mark Jones,2 Guo-Bao Tian,1,3
Anthony W. Pasculle,1,4 and Yohei Doi1*
Division of Infectious Diseases1 and Clinical Microbiology Laboratory,4 University of Pittsburgh Medical Center, Pittsburgh,
Pennsylvania; University of Queensland UQ Centre for Clinical Research, Royal Brisbane and Women’s Hospital,
Brisbane, Australia2; and Animal Disease Prevention and Food Safety Key Laboratory of Sichuan Province,
School of Life Sciences, Sichuan University, Chengdu, China3
Received 10 June 2010/Returned for modification 25 August 2010/Accepted 11 November 2010
Ampicillin-sulbactam is commonly used as an empirical therapy for invasive infections where Escherichia coli
is a potential pathogen. We evaluated the clinical and microbiologic characteristics of bloodstream infection
due to E. coli, with focus on cases that were nonsusceptible to ampicillin-sulbactam and not producing
extended-spectrum -lactamase (ESBL). Of a total of 357 unique bacteremic cases identified between 2005 and
2008, 111 (31.1%) were intermediate or resistant to ampicillin-sulbactam by disk testing. In multivariate
analysis, a history of liver disease, organ transplant, peptic ulcer disease, and prior use of ampicillin-sulbactam
were independent risk factors for bloodstream infection with ampicillin-sulbactam-nonsusceptible E. coli.
Among cases that received ampicillin-sulbactam as an empirical therapy, an early clinical response was
observed in 65% (22/34) of susceptible cases but in only 20% (1/5) of nonsusceptible cases. Among 50
ampicillin-sulbactam-resistant isolates examined, there was no clonal relatedness and no evidence of produc-
tion of inhibitor-resistant TEM (IRT). Instead, the resistance was attributed to hyperproduction of TEM-1
-lactamase in the majority of isolates. However, promoter sequences of blaTEM-1 did not predict resistance to
ampicillin-sulbactam. While the plasmid copy number did not differ between representative resistant and
susceptible isolates, the relative expression of blaTEM-1 was significantly higher in two of three resistant isolates
than in three susceptible isolates. These results suggest high-level blaTEM-1 expression as the predominant
cause of ampicillin-sulbactam resistance and also the presence of yet-unidentified factors promoting overex-
pression of blaTEM-1 in these isolates.
Ampicillin-sulbactam is a -lactam–-lactamase inhibitor
combination that has activity against a broad range of bacteria,
including Gram-positive, Gram-negative, and anaerobic organ-
isms. Available as an intravenous formulation in the United
States, it is commonly used for empirical management of var-
ious conditions such as bacteremia, pyelonephritis, pneumo-
nia, skin and soft tissue infections, and intra-abdominal infec-
tions (1). In the past, ampicillin-sulbactam has been active
against Escherichia coli, as sulbactam inhibits the TEM-1 -lac-
tamase that is produced by over 50% of E. coli isolates in some
countries (32).
Resistance to ampicillin-sulbactam has been increasing in E.
coli in the last decade. A worldwide survey of E. coli strains
isolated from intra-abdominal infections showed a rate of sus-
ceptibility to this combination of 46.3% in 2005, a drop from
55.5% in 2002 (3). At our institution, the susceptibility of E.
coli to ampicillin-sulbactam has been maintained relatively
well, but a decrease from 81% to 71% has been observed
between 2004 and 2007, raising concern that the agent may no
longer provide adequate coverage when used as empirical ther-
apy for suspected E. coli infection.
Mechanisms of resistance of E. coli to -lactam–-lactamase
combinations have been best studied for amoxicillin-clavulanic
acid. These include hyperproduction of plasmid-mediated
TEM-1 -lactamase (38), production of inhibitor-resistant
TEM (IRT) -lactamases (26, 35), production of plasmid-me-
diated -lactamases (including OXA-1 [39] and AmpC-type
-lactamases and extended-spectrum -lactamases [ESBLs] [17]),
and hyperproduction of chromosomal AmpC -lactamase (36).
Production of carbapenemases (for example, Klebsiella pneu-
moniae carbapenemase [KPC]) would also be expected to result
in resistance to -lactam–-lactamase combinations (28). Defi-
ciency of OmpC or OmpF porin does not affect the level of
resistance per se but may contribute to resistance when combined
with hyperproduction of TEM-1 (30). While there are relatively
few data regarding mechanisms of resistance to ampicillin-sulbac-
tam, it is believed that the same mechanisms affecting amoxicillin-
clavulanic acid affect ampicillin-sulbactam as well (8). The bulk of
the above data come from Europe, and data regarding mecha-
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nisms of resistance to -lactam–-lactamase combinations in iso-
lates from the United States have been limited. In light of the
continuing trend toward lower rates of susceptibility of E. coli to
ampicillin-sulbactam, the goal of the present study was 2-fold: (i)
to identify risk factors for and assess the clinical outcome of
bacteremia due to ampicillin-sulbactam-nonsusceptible E. coli
and (ii) to characterize the predominant mechanism of resistance
against this agent in these isolates.
MATERIALS AND METHODS
Study design and patients. A retrospective cohort of patients with bacteremia
due to E. coli was identified at the University of Pittsburgh Medical Center, an
834-bed tertiary teaching hospital with affiliated outpatient clinics, between 2005
and 2008. Cases confirmed as caused by ESBL-producing E. coli in the clinical
laboratory according to the criteria of the Clinical and Laboratory Standards
Institute (CLSI) (11) were excluded from both clinical analysis and laboratory
investigation. No carbapenem-resistant E. coli was present in the study sample.
Clinical data were collected from electronic medical records, deidentified, and
provided to the investigators. The study was approved by the Institutional Re-
view Board of the University of Pittsburgh.
Risk factors. Risk factors for bacteremia due to ampicillin-sulbactam-nonsus-
ceptible E. coli were investigated by comparing patients with bacteremia caused
by ampicillin-sulbactam-susceptible and -nonsusceptible isolates. The parame-
ters reviewed included the following: age; sex; race; source of infection; immune
status; presence of chronic renal failure, liver disease, chronic obstructive lung
disease, cardiovascular disease, peripheral vascular disease, cerebrovascular dis-
ease, peptic ulcer disease, or malignancy; history of organ transplant, transfer
from nursing home, prior use of antibiotics with activity against Gram-negative
organisms in the last 30 days, hospitalization, surgery, or intensive care unit
(ICU) admission in the last year; and the presence of a tracheostomy tube,
gastrostomy tube, intravenous line, or urinary catheter at the time of infection.
The Apache  score (19) and modified McCabe-Jackson classification (27) were
used to assess severity of illness and prognosis, respectively. An immunocom-
promised state was defined as the presence of diabetes mellitus, neutropenia, or
HIV infection, or receipt of steroids or other immunosuppressive therapy in the
last 30 days.
Clinical outcome measures. Patients with bacteremia due to E. coli were
monitored after the onset of bacteremia to assess early clinical response at 96 h
and 28-day mortality in response to antimicrobial therapy. Empirical antibiotic
therapy was defined as administration of an antibiotic with in vitro activity against
E. coli for at least 48 of the first 96 h after the first positive blood culture. Early
clinical response was defined by all of the following occurring before or at 96 h
from the time of first positive blood culture for a continuous 24-hour period: (i)
temperature from 36.0 to 37.9°C, (ii) white blood cell count of 4,000 to 10,900/l,
(iii) no requirement for vasopressors, and (iv) systolic blood pressure of greater
than 90 mm Hg. A case was documented as clinical failure when any of these
criteria was not met. The primary endpoints of the study were clinical response
at 96 h and mortality during the 28-day period after the first blood culture
positive for E. coli.
Susceptibility testing. For all available case-defining E. coli isolates, suscepti-
bility testing was conducted using the disk diffusion method for ampicillin, am-
picillin-sulbactam, amoxicillin-clavulanic acid, ticarcillin, ticarcillin-clavulanic
acid, piperacillin, piperacillin-tazobactam, cephalothin, cefoxitin, cefuroxime,
cefpodoxime, ceftazidime, cefotaxime, sulfamethoxazole-trimethoprim, gentami-
cin, and ciprofloxacin (BD, Sparks, MD). In addition, the MIC was determined
for ampicillin-sulbactam at a fixed ratio of 2:1 using the agar dilution method.
This method has been reported to better predict the in vitro antibacterial effect
of this agent than the one using a fixed concentration of sulbactam in an in vitro
pharmacokinetic model (15). Isolates that had high-level resistance to ampicillin-
sulbactam, as implied by the absence of any inhibitory zone, were selected for
further laboratory investigation, as described below.
aIEF. Analytical isoelectric focusing (aIEF) was performed as described pre-
viously (20). Enzyme activity was detected by placing filter paper soaked in 500
g/ml of nitrocefin over the focused gel. Isolates producing TEM-1, SHV-1, and
CMY-2 were used as controls.
PCR and sequencing. PCR analysis was performed to detect blaTEM-, blaSHV-,
and blaOXA-1-type -lactamase genes as previously described (4, 13). For isolates
that had a phenotype consistent with AmpC -lactamase production (i.e., re-
duced susceptibility to cefoxitin, cefuroxime, cefpodoxime, and ceftazidime),
multiplex PCR to detect known groups of plasmid-mediated AmpC -lactamases
was conducted (29).
For isolates that were positive for the blaTEM gene, a second PCR to amplify
the entire coding region as well as the promoter region was conducted using
primers TEM prom F (5-ATAAAATTCTTGAAGAC-3) and TEM prom R
(5-TTACCAATGCTTAATCA-3). Sequencing of the amplified products was
conducted with the same primers as well as two internal primers (461F [5-GG
GCAAGAGCAACTCGG-3] and 478R [5-ACCGAGTTGCTCTTGCCC-3])
using an ABI3730 instrument (Applied Biosystems, Foster City, CA).
Phylogenetic typing and PCR-based detection of the O25b-ST131 clone were
performed as described by Clermont et al. (9, 10).
Transformation of plasmids mediating ampicillin-sulbactam resistance. Plas-
mids were extracted from the study isolates using the alkaline lysis method as
previously described (34) and transformed into E. coli DH10B by electropora-
tion. Transformants were selected on LB agar containing 50 g/ml of ampicillin
(Sigma-Aldrich, St. Louis, MO). The transformants underwent susceptibility
testing as well as PCR analysis to confirm transfer of the blaTEM gene.
PFGE. The study isolates were subjected to pulsed-field gel electrophoresis
(PFGE) to evaluate for clonality. Genomic DNA was prepared as described
previously (31), digested with XbaI (New England Biolabs, Ipswich, MA), and
subjected to electrophoresis using a CHEF DR III system (Bio-Rad, Hercules,
CA) at 6 V with pulse time of 2.2 to 54.2 s and linear ramping at 14°C for 22 h.
A lambda ladder (New England Biolabs, Ipswich, MA) was used as the DNA size
marker. The relatedness of PFGE patterns was determined by the unweighted-
pair group method using average linkages and the DICE setting clustering
analysis on the Bionumerics software version 4.0 (Applied Maths, Sint-Martens-
Latem, Belgium). The results were interpreted based on the criteria described by
Tenover et al. (37).
Copy number assay. To determine whether there were differences in the copy
number of blaTEM-positive plasmid between isolates with high and low ampicil-
lin-sulbactam MICs, three blaTEM-positive isolates with high ampicillin-sulbac-
tam MICs (two with 256/128 g/ml and one with 512/128 g/ml) and three
blaTEM-positive isolates with low MICs (two with 32/16 g/ml and one with 16/8
g/ml) were selected. The isolates used in this assay were clonally unrelated as
determined by PFGE.
The copy number assay was conducted using primer pairs specific to blaTEM
and dxs, a housekeeping gene, as described previously (22). Genomic DNA was
extracted using the DNeasy blood and tissue kit (Qiagen, Valencia, CA) and
assayed with a 7500 real-time system (Applied Biosystems) with the initial hot
start of 95°C for 10 min and then 40 cycles of 95°C for 15 s and 58.5°C for 1 min.
Relative copy number difference was determined using the 2CT calculation as
previously described (22).
Relative quantification of blaTEM expression. The same isolates used in the
copy number assay were included in the expression study. For extraction of total
RNA, 30 ml of Luria-Bertani (LB) broth was inoculated with three colonies from
a blood agar plate incubated overnight for each of the six isolates. Cultures were
incubated at 37°C with shaking (150 rpm) until they reached an optical density at
600 nm (OD600) of 0.5, at which point the bacteria was harvested. Total RNA was
extracted using the RNeasy maxikit (Qiagen) according to the manufacturer’s
instructions.
After treatment with DNase I (Ambion, Austin, TX), RNAs from all six
isolates were reverse transcribed into cDNAs using the High Capacity RNA to
cDNA kit (Applied Biosystems) with the same primer pairs specific to blaTEM
and dxs that were used in the copy number assay. The cDNA was run in an
Applied Biosystems 7500 real-time system with the initial hot start of 95°C for 10
min and then 40 cycles of 95°C for 15 s and 58.5°C for 1 min. Nontemplate and
non-reverse transcriptase controls were included for each run. Dissociation
curves were also obtained to analyze the specificity of the PCR products.
A primer concentration of 400 nM each for blaTEM and dxs and 10 ng of
template RNA were found to be optimal. Validation of the 2CT method was
performed by measuring the efficiencies of blaTEM and dxs amplification. The
amplification efficiency (E) of each target was determined by comparing ampli-
fications using a serial dilution of RNA sample and calculating E using a previ-
ously described equation (22). The expression of dxs was used to normalize the
relative expression data for blaTEM. The cycle thresholds (CT) for each gene were
averaged using biological duplicates, and the relative expression was calculated
using RQ  2CT (25).
Statistical analysis. A multivariable logistic regression model was used to
assess the risk factors. The logistic model was developed by entering all variables
that had P values of 0.2 in the univariate analyses into the initial model.
Estimated odds ratios (ORs) and 95% confidence intervals (CIs) were estimated
from this model. For the outcome analyses, the chi-square test, Fisher exact test,
or median unbiased estimate was used to compare categorical variables, and the
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Mann-Whitney U test was used to compare continuous variables. All analyses
were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC), and a P
value of 0.05 was considered statistically significant.
RESULTS
Study population. A total of 370 cases of E. coli bacter-
emia were identified during the period between July 2005
and January 2008. Of these, 13 cases were excluded since
they were caused by strains that were confirmed as produc-
ing ESBL by the phenotypic method endorsed by the CLSI
(11). Of the remainder, 111 (31.1%) cases were reported as
nonsusceptible to ampicillin-sulbactam using the disk diffu-
sion testing in the clinical microbiology laboratory and con-
stituted the case group in the clinical analysis. Sixty-three of
the 111 cases were resistant to ampicillin-sulbactam, of
which 50 had corresponding isolates available for laboratory
studies.
Risk factors. The demographics of the patients and risk
factors associated with bacteremia due to ampicillin-sulbac-
tam-nonsusceptible and -susceptible isolates are listed in Table
1. The ampicillin-sulbactam-nonsusceptible cases were more
likely than the ampicillin-sulbactam-susceptible cases to be
male. The degrees of health care exposure were similar in both
groups, and accordingly, there was no significant difference in
terms of the site of acquisition (community associated, health
care associated, or hospital acquired) (data not shown). Sever-
ities of illness, as measured by median Apache II score and use
of vasopressors, were comparable, and urine was the most
common primary source of bacteremia in both groups. Risk
factors that revealed significant association with nonsuscepti-
bility in the univariate analysis included history of solid organ
transplant and peptic ulcer disease. In regard to antimicrobial
use in the previous 28 days, the use of ampicillin-sulbactam was
a significant risk factor for ampicillin-sulbactam nonsuscepti-
bility.
In the multivariate analysis, a history of liver disease, peptic
ulcer disease, or organ transplant and prior use of ampicillin-
sulbactam remained as independent risk factors for ampicillin-
sulbactam nonsusceptibility (Table 1).
Clinical outcome. Clinical cure was achieved within 96 h in
60 (55%) and 146 (60%) of the patients in nonsusceptible and
susceptible groups, respectively. The mortalities within 28 days
were 20% and 17% for these two groups, respectively (P 
0.6). Among patients who received ampicillin-sulbactam as the
empirical therapy, 65% (22/34) of those with a susceptible
isolate and 20% (1/5) of those with a nonsusceptible isolate
had clinical cure within 96 h (P  0.14). Among patients with
ampicillin-sulbactam-nonsusceptible isolates, 73% (29/40) of
those who received appropriate empirical therapy (i.e., with an
agent to which the isolate was susceptible) and 30% (3/10) of
those who received inappropriate empirical therapy (i.e., with
an agent to which the isolate was nonsusceptible, including
ampicillin-sulbactam) attained clinical cure within 96 h (P 
0.02).
Susceptibility testing. Of the 63 ampicillin-sulbactam-resis-
tant cases, isolates for 50 cases were available for further stud-
ies in the research laboratory. Upon MIC testing, 46 (92%)
were resistant and 4 (8%) were intermediate to ampicillin-
sulbactam. Susceptibility testing results for these 50 isolates
with other -lactams and penicillin–-lactamase inhibitor com-
binations are shown in Table 2. For non--lactam agents, the
rates of nonsusceptibility to gentamicin, ciprofloxacin, and sul-
famethoxazole-trimethoprim were 12, 26, and 60%, respec-
tively. None of these isolates possessed a phenotype consistent
with production of known inhibitor-resistant TEM (IRT)
-lactamases, i.e., susceptibility to cephalothin (8). Thirty of
the 50 isolates gave no inhibitory zone around the ampicillin-
sulbactam disk, which was suggestive of high-level resistance to
this agent.
PFGE, phylogenetic typing, and O25b-ST131 detection. A
dendrogram of the 50 available isolates constructed from
PFGE revealed no clustering of the study isolates, indicating
that they were not clonally related (data not shown). The
distribution of phylogenetic types was as follows: A, 11 isolates
(22%); B1, 3 isolates (6%); B2, 26 isolates (52%); and D, 10
isolates (20%). Of the 26 isolates belonging to phylogenetic
type B2, 9 isolates (34.6%) were identified as O25b-ST131
using the PCR-based method.
aIEF. Analytical IEF was performed on 37 representative
isolates. It revealed a strong band at a pI of 5.4 in all except one
isolate, consistent with the presence of TEM-1. Additional
bands consistent with SHV-1 (pI, 7.6) and OXA-1 (pI, 7.3)
were observed for two and one isolates, respectively, in a man-
ner consistent with the PCR results described below, except for
one isolate which was positive for blaOXA-1 by PCR but for
which a band corresponding to OXA-1 could not be visualized
by aIEF.
PCR for -lactamase genes. All four isolates that were non-
susceptible to ceftazidime were positive by PCR for the pres-
ence of a plasmid-mediated AmpC -lactamase gene, includ-
ing three isolates with a CMY-2-type -lactamase and one
isolate with a FOX-type -lactamase. Forty-eight (96%), 3
(6%) and 4 (8%) isolates were positive for the blaTEM, blaSHV,
and blaOXA-1 genes, respectively.
Transformants with ampicillin resistance. Of the 30 clinical
isolates that gave no inhibitory zone around the ampicillin-
sulbactam disk, three carried CMY-2 or FOX-type -lacta-
mase genes by PCR, accounting for this phenotype. Of the
remaining 27 isolates, all isolates except one were positive for
the blaTEM gene by PCR, whereas two and three isolates were
also positive for SHV and OXA-1, respectively. Plasmids were
purified from these isolates and used to transform E. coli
DH10B. As a result, ampicillin-resistant transformants were
obtained from 23 of the 27 isolates. All these transformants
were positive for the blaTEM gene by PCR, whereas one was
positive for the OXA-1 gene as well. The MICs of ampicillin-
sulbactam for the 27 clinical isolates and their transformants,
when available, are listed in Fig. 1. The MICs for the clinical
isolates and their transformants correlated well within the
range of 32/16 to 128/64 g/ml. However, increases in MICs
over 128 g/ml did not appear to be inherited by the transfor-
mants.
Sequencing of the blaTEM gene and its promoter region. The
blaTEM gene was sequenced for 22 of the 26 clinical isolates
that gave no inhibitory zone around the ampicillin-sulbactam
disk, were positive for the blaTEM gene, and were negative for
plasmid-mediated AmpC -lactamase genes. All sequences
were consistent with TEM-1. The entire promoter region was
further sequenced for 11 of these isolates. They were selected
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TABLE 1. Risk factors for ampicillin-sulbactam nonsusceptibility with E. coli bacteremia
Type of analysis and variable
Valuea for:
P value OR 95% CI
Cases (n  111) Controls (n  246)
Univariate analysis
Demographics
Median age, yr (range) 60 (21–96) 63 (20–94)
Age 65 yr 41 (36.9) 112 (45.5) 0.13 0.70 0.44, 1.11
Male gender 58 (52.3) 98 (39.8) 0.03 1.65 1.05, 2.60
White 81 (76.4) 176 (77.9) 0.77 0.92 0.53, 1.59
Black 22 (20.8) 44 (19.5) 0.78 1.08 0.61, 1.92
Health care exposures
Admitted from nursing home 23 (20.7) 42 (17.1) 0.41 1.27 0.72, 2.24
Prior surgery within 30 days 15 (13.5) 28 (11.4) 0.58 1.21 0.62, 2.37
Any hospitalization in past yr 88 (79.3) 193 (78.5) 0.86 1.05 0.61, 1.82
Any ICU admission in past yr 33 (29.7) 63 (25.6) 0.42 1.23 0.75, 2.02
Any surgery in past yr 32 (28.8) 55 (22.4) 0.19 1.41 0.85, 2.34
Dialysis in past yr 10 (9.0) 26 (10.6) 0.65 0.84 0.39, 1.80
Outpatient intravenous therapy in past yr 5 (4.5) 7 (2.8) 0.42 1.61 0.50, 5.19
Devices
Tracheostomy tube 4 (3.6) 14 (5.7) 0.41 0.62 0.20, 1.93
Gastrostomy tube 2 (1.8) 2 (0.8) 0.42 2.24 0.31, 16.10
Indwelling urinary catheter 20 (18.0) 28 (11.4) 0.09 1.71 0.92, 3.19
Vascular catheter 60 (54.1) 118 (48.0) 0.29 1.28 0.81, 2.00
Underlying conditions
Diabetes 27 (24.3) 83 (33.9) 0.07 0.63 0.38, 1.04
Chronic obstructive pulmonary disease 5 (4.5) 26 (10.6) 0.07 0.40 0.15, 1.06
Cardiovascular disease 27 (24.3) 57 (23.3) 0.83 1.06 0.63, 1.79
Peripheral vascular disease 1 (0.9) 2 (0.8) 0.93 1.11 0.10, 12.32
Cerebrovascular disease 4 (3.6) 16 (6.5) 0.27 0.54 0.17, 1.64
Immunocompromised 59 (53.2) 122 (49.6) 0.53 1.15 0.74, 1.81
Chronic renal failure 12 (10.8) 22 (9.0) 0.59 1.23 0.58, 2.58
Peptic ulcer disease 6 (5.4) 1 (0.4) 0.02 13.9 1.66, 117.12
Liver disease 22 (19.8) 29 (11.8) 0.05 1.84 1.00, 3.38
Malignancy 8 (7.2) 23 (9.4) 0.50 0.75 0.32, 1.73
Transplant 30 (27.0) 39 (15.9) 0.02 1.96 1.14, 3.36
Sources of bacteremia
Pneumonia (baseline) 4 (3.6) 14 (5.7) 0.26
UTI 49 (44.1) 103 (41.9) 1.67 0.52, 5.32
Intra-abdominal 6 (5.4) 7 (2.8) 3.00 0.63, 14.23
Line related 5 (4.5) 14 (5.7) 1.25 0.28, 5.65
Other 4 (3.6) 1 (0.4) 14.00 1.20, 163.37
Unknown 43 (38.7) 107 (43.5) 1.41 0.44, 4.51
Severity of illness
Mean Apache II score (range) 11 (0–42) 11 (0–35)
Apache II score of 25 9 (8.7) 16 (6.9) 0.56 1.28 0.55, 3.01
Vasopressor use 18 (16.4) 39 (16.0) 0.94 1.02 0.56, 1.88
Antimicrobials in 28 days prior to bacteremia
Any 29 (26.1) 38 (15.4) 0.02 1.94 1.12, 3.34
Oxyimino-cephalosporinsb 1 (0.9) 6 (2.4) 0.35 0.36 0.04, 3.06
-Lactam–-lactamase inhibitor combinationsc 16 (14.4) 17 (6.9) 0.03 2.27 1.10, 4.68
Ampicillin-sulbactam 13 (11.7) 7 (2.8) 0.002 4.53 1.75, 11.69
Carbapenemsd 0 (0.0) 1 (0.4) 1.00 2.22 0.00, 86.43
Fluoroquinolonese 2 (1.8) 7 (2.8) 0.56 0.63 0.13, 3.07
Multivariate analysis
Ampicillin-sulbactam in 28 days prior to bacteremia 0.011 3.651 1.35, 9.85
Liver disease 0.019 2.131 1.13, 4.00
Peptic ulcer disease 0.012 15.837 1.84, 136.46
Transplant 0.024 1.945 1.09, 3.46
a Unless otherwise indicated, values are number (percentage) of cases.
b Cefuroxime, cefotaxime, ceftriaxone, ceftazidime, and cefepime.
c Ampicillin-sulbactam, amoxicillin-clavulanate, and piperacillin-tazobactam.
d Ertapenem, imipenem, and meropenem.
e Ciprofloxacin, levofloxacin, and moxifloxacin.
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among the 26 isolates to represent various MICs of ampicillin-
sulbactam. Several promoter sequences have been implicated
in differential expression of the TEM-1 -lactamase in E. coli
(21). Of the 11 isolates, 6 isolates had the regular P3 promoter,
whereas 5 isolates had the Pa/Pb promoter. The ampicillin-
sulbactam MICs of the isolates with the P3 promoter were
32/16 (n  2), 128/64 (n  2), and 512/256 (n  2) g/ml.
Those of isolates with the Pa/Pb promoter were 64/32 (n  3)
and 256/128 (n  2) g/ml.
Copy numbers of blaTEM-carrying plasmids. The average
copy numbers of blaTEM-carrying plasmids from the three iso-
lates with high ampicillin-sulbactam MICs (256/128 to 512/256
g/ml) and the three isolates with low ampicillin-sulbactam
MICs (32/15 g/ml) were calculated to be 4.1 and 3.5 copies
per cell, respectively.
Relative quantification of blaTEM expression. The relative
expression of the blaTEM gene in the three isolates with high
ampicillin-sulbactam MICs was calculated to be an average of
3.4-fold higher than that in the three isolates with low ampi-
cillin-sulbactam MICs. As shown in Fig. 2, two of the three
isolates with high ampicillin-sulbactam MICs (isolates A and
C) had significantly higher expression of blaTEM-1 than the
three isolates with low MICs (isolates D to F). Isolate B, which
had an ampicillin-sulbactam MIC of 512/256 g/ml, however,
did not demonstrate high-level expression of blaTEM-1.
DISCUSSION
Due to its wide spectrum of activity, which includes activity
against Gram-positive, Gram-negative, and anaerobic bacteria,
ampicillin-sulbactam has been commonly used to treat infec-
tions such as urinary tract infections (UTI), community-ac-
quired pneumonia, skin and soft tissue infection, and bacter-
emia. This wide spectrum is achieved by the addition of
sulbactam, which inhibits most Ambler’s class A -lactamases
that are present in numerous species, including E. coli. Ampi-
cillin-sulbactam has therefore been considered an adequate
empirical choice when E. coli is suspected to be involved in an
infection. In recent years, however, resistance to this agent has
become common in E. coli, reaching approximately 50% in
some series from the United States (2, 14). Data from Euro-
pean countries suggest production of inhibitor-resistant TEM
(IRT) -lactamases as a major mechanism for this resistance,
among others (8), but IRT has been reported for only a small
number of isolates in the United States (6, 17). The purpose of
the present study was to investigate the clinical features of
bacteremia due to ampicillin-sulbactam-nonsusceptible E. coli
and the mechanisms underlying the resistance.
Prior use of ampicillin-sulbactam was a strong independent
risk factor for nonsusceptibility to this agent. Although we did
not use the more rigorous case-case-control study design, this
finding was in line with a previous study by Kaye et al., which
identified prior administration of the penicillin class of antimi-
crobials, including ampicillin-sulbactam, as an independent
risk factor for acquisition of ampicillin-sulbactam-nonsuscep-
tible E. coli (18). This suggests that repeated courses of this
agent put patients at substantial risk for a nonsusceptible or-
ganism, especially given the already high background rates of
resistance to this agent. Histories of liver disease, organ trans-
plant, and peptic ulcer disease were the other independent risk
factors. The former two risk factors probably reflect the char-
acteristics of our center, which has a robust organ transplant
program. The significance of peptic ulcer disease was unclear
given very small number of patients who had this condition in
either group.
The 28-day mortality rates were 20 and 17% for nonsuscep-
tible and susceptible cases, respectively, and over half of the
patients in both groups had clinical cure within 96 h. However,
among the five patients with a nonsusceptible organism who
received empirical therapy with ampicillin-sulbactam, four ex-
perienced delayed clinical cure, whereas 22 of 34 patients with
a nonsusceptible organism who received an appropriate em-
pirical therapy had clinical cure within 96 h. This suggests that
discordant therapy may indeed have some negative clinical
impact. However, a larger sample size is necessary to make
more rigorous comments about this observation.
The distribution of phylogenetic groups was consistent with
other reports on bacteremic strains documenting the predom-
inance of group B2, which is considered the most virulent
among the four groups (5, 7, 12, 33). The finding of the pres-
ence of the O25b-ST131 clone among group B2 isolates is also
in agreement with recent studies suggesting that this clone is
now distributed among non-ESBL-producing as well as ESBL-
producing E. coli strains (5, 16, 23).
We did not find any isolate with the phenotype commonly
seen in IRT production. IRT is a relatively common mecha-
FIG. 1. Dot plot of MICs of ampicillin-sulbactam-resistant E. coli
bacteremic isolates and their blaTEM-1-positive transformants.
TABLE 2. -Lactam susceptibilities of 50 ampicillin-sulbactam-
resistant E. coli bacteremic isolates
Antimicrobial
No. (%) of isolates
Susceptible Intermediate Resistant
Ampicillin 0 (0) 0 (0) 50 (100)
Amoxicillin-clavulanate 1 (2) 8 (16) 41 (82)
Ticarcillin 0 (0) 0 (0) 50 (100)
Ticarcillin-clavulanate 4 (8) 26 (52) 20 (40)
Piperacillin 0 (0) 2 (4) 48 (96)
Piperacillin-tazobactam 36 (72) 8 (16) 6 (12)
Cephalothin 0 (0) 6 (12) 44 (88)
Cefoxitin 40 (80) 2 (4) 8 (16)
Cefuroxime 28 (56) 7 (14) 15 (30)
Ceftazidime 46 (92) 1 (2) 3 (6)
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nism of resistance to amoxicillin-clavulanate, along with hyper-
production of the chromosomal class C -lactamase in some
European countries, especially France (8, 24). Our finding is
consistent with previous reports documenting the rarity of
IRTs in the United States (6, 17). Instead, the majority of
isolates with high-level resistance to ampicillin-sulbactam were
able to reproduce a similar degree of resistance to this agent in
the corresponding transformants that received plasmids encod-
ing TEM-1, implicating hyperproduction of TEM-1 as the pre-
dominant reason for this resistance. We then investigated the
mechanism underlying TEM-1 hyperproduction, with the hy-
pothesis that it would be due to either a higher copy number of
the blaTEM-1-encoding plasmids or overexpression of blaTEM-1
due to modifications of the promoter. Indeed, we found that
the copy numbers of blaTEM-1-carrying plasmids were equiva-
lent in isolates with higher and lower MICs of ampicillin-
sulbactam, making this less likely to be the cause of TEM-1
hyperproduction. Instead, two of the three isolates with higher
MICs displayed significantly higher levels of blaTEM-1 expres-
sion than those with lower MICs, which accounted for TEM-1
hyperproduction in these isolates. Promoter sequence varia-
tions that have been associated with overexpression of
blaTEM-1 (21), however, could not be identified consistently.
This suggests the presence of a yet-unidentified mechanism
driving overexpression of blaTEM-1 and requires further inves-
tigation. Also, there were a number of isolates whose ampicil-
lin-sulbactam MICs did not correlate well with those of their
corresponding transformants, as seen in Fig. 1. Mechanisms
other than hyperproduction of TEM-1, such as porin defi-
ciency, may account for the resistance in these isolates.
In conclusion, nonsusceptibility to ampicillin-sulbactam is
common among bacteremic E. coli isolates. Prior use of this
agent is a strong risk factor for this resistance. While the 28-day
mortalities are comparable for bacteremia due to these isolates
and susceptible isolates, patients with nonsusceptible isolates
may experience a delayed clinical response when empirical
therapy is discordant. The predominant mechanism of ampi-
cillin-sulbactam resistance in E. coli is hyperproduction of
TEM-1, which likely represents an evolutionary response to
overcome selective pressure from -lactam–-lactamase inhib-
itor combinations, especially ampicillin-sulbactam.
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